Please provide your email address to receive an email when new articles are posted on . A February study by Katherine M. Jackson, MD, of the department of surgical oncology at St. John's Cancer ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved the novel immunotherapy denileukin diftitox-cxdl for treatment of certain patients with ...

Skin (cutaneous) lymphomas often manifest as a skin rash. Although usually identified early, skin lymphomas can be mistaken for other skin conditions, delaying diagnosis. Non-Hodgkin's lymphoma (NHL) ...

One researcher explains the science behind Lymphir, recently approved by the FDA for relapsed/refractory cutaneous T-cell lymphoma. The recent approval by the Food and Drug Administration (FDA) of ...

Lymphir, an immunotherapy, has been approved by the FDA to treat patients with relapsed or refractory cutaneous T-cell lymphoma. The Food and Drug Administration has approved Lymphir (denileukin ...